Purpose: The natural history of nonclear cell renal cell carcinoma following surgery with curative intent remains poorly defined with postoperative surveillance informed by guidelines largely intended for clear cell renal cell carcinoma. We evaluated relapse patterns and potential implications for post-nephrectomy surveillance in patients with nonclear cell renal cell carcinoma enrolled in the E2805 trial, the largest randomized trial of adjuvant antiangiogenic therapy of high risk renal cell carcinoma. Materials and Methods: We retrospectively analyzed the records of patients with completely resected nonclear cell renal cell carcinoma. Participants received up to 54 weeks of postoperative therapy with sunitinib, sorafenib or placebo and underwent surveillance imaging at standardized intervals for 10 years. For recurrence rates by site the cumulative incidence was estimated, accounting for competing risks. The adequacy of strict adherence to post-nephrectomy surveillance guidelines was evaluated. Results: A total of 403 patients with nonclear cell renal cell carcinoma were enrolled in the study. During a median followup of 6.2 years 36% of nonclear cell renal cell carcinomas recurred. Five-year recurrence rates were comparable for nonclear and clear cell renal cell carcinoma in the 1,541 patients, including 34.6% (95% CI 29.8e39.4) and 39.5% (95% CI 36.9e42.1), respectively. However, patients with nonclear cell renal cell carcinoma were significantly more likely to have abdominal sites of relapse (5-year recurrence rate 26.4% vs 18.2%, p ¼ 0.0008) and significantly less likely to experience relapse in the chest (5-year recurrence rate Accepted for publication August 8, 2018. The corresponding author certifies that, when applicable, a statement(s) has been included in the manuscript documenting institutional review board, ethics committee or ethical review board study approval; principles of Helsinki Declaration were followed in lieu of formal ethics committee approval; institutional animal care and use committee approval; all human subjects provided written informed consent with guarantees of confidentiality; IRB approved protocol number; animal approved project number.
ACCOUNTING for approximately 25% of all RCCs, nonccRCC represents a heterogeneous group of rare kidney cancers. 1 Importantly nonccRCC shows clinical behavior and disease biology distinct from conventional ccRCC, including various genetic alterations and druggable pathways specific to nonccRCC histologies. 2, 3 However, despite these observed differences the optimal management of nonccRCC remains unknown largely due to a paucity of clinical studies specific to this patient population. Across the nonccRCC disease stage spectrum the current clinical management relies heavily on evidence extrapolated from wellestablished ccRCC treatment regimens, often despite the recognition of suboptimal clinical outcomes. 4, 5 In particular the natural history of nonccRCC following surgery with curative intent remains poorly defined with postoperative surveillance strategies derived from consensus guidelines that are largely intended for ccRCC. 6, 7 Prior reports describing clinical outcomes in patients with nonccRCC primarily consist of small retrospective studies of heterogeneous populations, including patients with medullary carcinoma or collecting duct histologies, which lack information on relapse patterns or focus exclusively on patients with metastatic disease. 2, 8, 9 Furthermore, available postoperative prognostic risk models focus primarily on ccRCC populations. 10 Therefore, improved understanding of the relapse patterns of resected nonccRCC histologies is critical to inform patient counseling and optimal surveillance strategies in this under studied population.
We evaluated relapse patterns and the implications for post-nephrectomy surveillance in patients with nonccRCC enrolled in the first and largest randomized trial of adjuvant antiangiogenic therapy of high risk RCC.
MATERIALS AND METHODS
This was a retrospective analysis of all patients with nonccRCC enrolled in the ECOG-ACRIN (Eastern Cooperative Oncology Group-American College of Radiology Imaging Network) E2805, a double-blind, placebo controlled, randomized, phase III trial of adjuvant sunitinib or sorafenib antiangiogenic therapy in patients with resected local disease at high risk for recurrence (NCT 00326898). 11 Importantly to our knowledge the E2805 trial is the only reported phase III trial of adjuvant antiangiogenic systemic therapy to include patients with nonccRCC histologies.
Study eligibility and treatment algorithms were previously described. 11 Briefly eligible patients with intermediate or high risk (T1b or greater, grade 3-4, N0) ccRCC or nonccRCC within 12 weeks of complete primary tumor resection received up to 54 weeks of sunitinib, sorafenib or placebo therapy postoperatively. Protocol followup consisted of cross-sectional imaging of the chest, abdomen and pelvis every 4.5 months during treatment, every 6 months for 2 years and then at least annually for 10 years regardless of pathological tumor stage. A central pathology review was performed. This study was approved by the Institutional Review Board at each site.
The Kaplan-Meier method was used to estimate disease-free survival, defined as time from randomization to disease recurrence, second primary cancer development or death from any cause. The log rank test was applied to evaluate survival differences between groups. Disease recurrence and relapse sites were according to investigator assessment. Relapse sites in the chest included pulmonary parenchyma, thoracic lymphadenopathy and pleural disease. Abdominal relapse sites included the nephrectomy bed, abdominopelvic lymphadenopathy, a hepatic mass, and abdominal wall and peritoneal disease.
To determine RRs by site the cumulative incidence was estimated, accounting for competing risks, including recurrence at other sites, development of a second primary cancer or death. The Gray test was used to compare the incidence between groups. Multivariable Fine-Gray competing risks regression models were constructed to further explore the effect of nonccRCC histology on the observed clinical relapse pattern (chest vs abdominal relapse). Differences were considered significant at p <0.05. The current NCCN and AUA recommendations were applied to evaluate the adequacy of strict adherence to post-nephrectomy consensus surveillance guidelines through 5 years. 6, 7 
RESULTS
Overall 403 patients with nonccRCC were enrolled in the E2805 trial 11 and included in analysis, including 135, 130 and 138 in the sunitinib, sorafenib and placebo arms, respectively. Supplementary table 1 (http://jurology.com/) lists patient characteristics at study entry. Of the 403 patients 191 (47%) were categorized as at very high risk by the UISS prognostic criteria. 12 Of the patients 63% underwent an open surgical approach and 93% underwent radical nephrectomy.
Of the 403 nonccRCC cases 144 (36%) recurred and were detected during a median followup of 6.2 years. The 5-year RR was 22.0% (95% CI 11.5e28.1) and 48.6% (95% CI 41.0e55.7) in the intermediate high and very high UISS risk groups, respectively.
12
In keeping with the overall E2805 trial findings 11 there was no significant difference in disease-free survival and overall survival across treatment groups in patients with nonccRCC histologies (log rank p ¼ 0.28 and 0.44, respectively, fig. 1 ).
Baseline characteristics of nonccRCC and ccRCC in 1,541 patients were comparable (supplementary table 2, http://jurology.com/). Five-year RRs were comparable in nonccRCC and ccRCC cases (34.6%, 95% CI 29.8e39.4 and 39.5%, 95% CI 36.9e42.1, respectively, fig. 2, A) . However, significant differences were observed in relapse patterns. Among nonccRCC cases abdominal recurrence was most frequently identified, including the lymph nodes in 39%, the nephrectomy bed in 17% and the liver in 13%. Compared to patients with ccRCC those with nonccRCC were significantly more likely to have abdominal relapse sites (5- No significant differences were observed in relapse sites in patients with nonccRCC or ccRCC based on the assigned adjuvant treatment group, including sunitinib, sorafenib or placebo (table 3) .
To further assess the potential impact of assigned adjuvant treatment on observed relapse patterns we restricted additional exploratory analysis to the population of patients with nonccRCC and ccRCC who were randomized to placebo. This additional analysis also indicated differences in relapse pattern by RCC histology. Among patients randomized to placebo 5-year RRs were comparable for nonccRCC and ccRCC histologies (34.6%, 95% CI 26.5e42.9 and 37.1%, 95% CI 32.7e41.5, respectively). However, when compared to ccRCC, patients with nonccRCC had a numerically higher rate of abdominal relapse (5-year RR 27.8% vs 16.0%) and a lower rate of chest relapse (5-year RR 13.6% vs 19.3%).
Based on strict adherence to consensus guidelines surveillance imaging would be required for 5.3 years to capture 95% of nonccRCC abdominal recurrences. Strict adherence to the current NCCN GuidelinesÒ or the AUA guidelines through 5 years would potentially capture approximately 91% of relapses at any site regardless of UISS risk stratification (table 4) . Of the 144 nonccRCC recurrences 13 (9%) developed beyond 5 years postoperatively. The histological subtype was papillary in 6 cases, chromophobe in 3 and mixed in 4.
DISCUSSION
There remains limited knowledge regarding the natural history, relapse patterns, and optimal surveillance and treatment in patients with nonccRCC. 1 Prior reports on relapse patterns of resected RCC have been largely limited to long-term ccRCC followup. 13 To our knowledge we report the largest evaluation of the natural history of nonccRCC following curative intent nephrectomy with standardized patient followup and annotation of relapse sites. Our findings indicate that while overall 5-year RRs were comparable in patients with nonccRCC and those with ccRCC, patients with nonccRCC appeared to demonstrate a distinct pattern of relapse characterized by more abdominal site recurrence and less frequent chest relapse. In addition, no difference was identified in relapse site based on the adjuvant In some patients recurrence developed at more than 1 site.
treatment group, which is in keeping with reported findings in similar adjuvant studies restricted to only patients with ccRCC.
14 Characterizing relapse patterns in patients at high risk for recurrence may have important implications for operative technique and postoperative surveillance. The apparently increased rate of abdominal site relapse in nonccRCC cases raises the hypothesis of potential benefit from intensified abdominal surveillance and/or consideration of additional local therapy. For example, given the current lack of highly effective systemic therapies for nonccRCC histologies, there may be a greater role for more extensive local surgery such as empirical lymphadenectomy. Indeed, in 39% of the patients with nonccRCC in this cohort the first relapse developed in the abdominal lymph nodes. In addition, intensified abdominal surveillance may enable the identification of disease relapse at earlier stages, potentially enabling metastatectomy or other local salvage therapies. 15, 16 Ideally such intensified imaging surveillance would capture recurrence using the appropriate test at the optimal timepoint. For example, abdominal imaging with ultrasound, computerized tomography or magnetic resonance imaging is allowable as surveillance modalities according to the AUA guidelines. However, our findings suggest a potential advantage for cross-sectional imaging over ultrasound imaging for more sensitive abdominal surveillance in this population at apparent higher risk for abdominal relapse.
Furthermore, controversy exists regarding the optimal surveillance duration following localized RCC treatment and current guidelines counsel a risk stratified approach with imaging for approximately 5 years in higher risk subgroups. 6, 7, 17 However, there is limited information on the adequacy of these recommendations in nonccRCC subgroups. The AUA guidelines and the NCCN Guidelines do not distinguish the surveillance duration based on histology and they leave aspects of followup protocols to physician discretion.
Although the standardized surveillance imaging frequency in the E2805 protocol 11 generally mirrors standard consensus guidelines, a significant distinction is the prolonged routine cross-sectional imaging surveillance performed for 10 years in patients in the E2805 trial. As 90% of clinical recurrences would potentially be detected by strict adherence to the AUA guidelines or the NCCN Guidelines, our data indicate that current guidelines are largely adequate but emphasize the importance of long-term followup beyond 5 years to capture approximately 10% of observed late nonccRCC recurrences. For example, such prolonged cross-sectional surveillance, particularly of the abdomen, may be warranted in younger and healthier individuals. Importantly the observed relapse patterns of and potential implications for population based surveillance and management cannot be definitively evaluated from this study. They will require careful validation, and evaluation of the impact on patient outcomes and societal costs.
A limitation of this analysis is the heterogeneous nature of nonccRCC and the potential for variable clinical courses based on individual nonccRCC subtypes (ie papillary type 1 vs type 2). It is possible that the observed increased risk of abdominal relapse may have been largely driven by specific histological subtypes in the nonccRCC category. However, given the rarity of these distinct subtypes, future followup of individual histology dependent outcomes will require ongoing pooled and cooperative efforts.
In addition, higher pathological tumor stage has been recognized as a prognostic feature for abdominal site relapse in prior RCC cohorts. 2, 13 Therefore, differences in the distribution of tumor stage across histologies may have influenced the observed relapse patterns. However, the proportion of In some patients recurrence developed at more than 1 site.
patients in each UISS risk group, which accounts for primary tumor staging, was similar across ccRCC and nonccRCC histologies, indicating a lack of confounding by tumor stage. 11 Because the E2805 study included a relatively high risk cohort of completely resected RCC cases, 11 these findings may not be generalizable to resected nonccRCC cases with lower estimated recurrence rates.
Finally, although no differences were found according to the assigned adjuvant therapy or placebo, it is possible that this analysis had limited power to detect differences in relapse pattern by treatment group. However, consistent findings in analyses restricted to placebo treated patients further strengthen the observed differences in relapse pattern. Further, recently reported findings in similar adjuvant antiangiogenic therapy studies also indicated a lack of effect of adjuvant therapy on observed relapse patterns. 14 
CONCLUSIONS
To our knowledge this is the largest standardized evaluation of the natural history of nonccRCC after nephrectomy with curative intent. Our findings suggest that nonccRCC shows a distinct pattern of relapse compared to conventional ccRCC and indicate the usefulness of continued long-term and cross-sectional imaging in patients with high risk, resected nonccRCC.
